Literature DB >> 19688614

A case of recurrent metastatic hepatocellular cancer controlled with immunotherapy and antiviral therapy following resection.

Saadettin Kilickap1, Ayse Kars, Erhan Hamaloglu, Halis Simsek.   

Abstract

Hepatocellular carcinoma (HCC) is the most frequent malignant tumour of the liver. The risk of HCC in chronically hepatitis B virus (HBV) infected individuals is approximately 100-fold higher than in the uninfected population. Despite all therapeutic advances, the benefit of systemic chemotherapy in patients with HCC has limited. But, the phase III clinical trial conducted in patients with advanced HCC treated with sorafenib has showed significant improvements in both overall and progression-free survival Metastasis from liver to extrahepatic tissues is reported to be quite uncommon and has a poor prognosis. Here we present a case of HCC which metastasized to the vertebrae, lung and kidney in order of appearance and controlled with immunotherapy and antiviral therapy following resection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19688614     DOI: 10.1007/s12032-008-9083-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  28 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance.

Authors:  Sang Hoon Ahn; Young Nyun Park; Jun Yong Park; Hye-Young Chang; Jung Min Lee; Ji Eun Shin; Kwang-Hyub Han; Chanil Park; Young Myoung Moon; Chae Yoon Chon
Journal:  J Hepatol       Date:  2005-02       Impact factor: 25.083

Review 3.  Epidemiological characteristics and risk factors of hepatocellular carcinoma.

Authors:  C J Chen; M W Yu; Y F Liaw
Journal:  J Gastroenterol Hepatol       Date:  1997-10       Impact factor: 4.029

4.  Hepatocellular carcinoma after long-term tamoxifen therapy.

Authors:  D F Moffat; K A Oien; J Dickson; T Habeshaw; D R McLellan
Journal:  Ann Oncol       Date:  2000-09       Impact factor: 32.976

Review 5.  Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives.

Authors:  P J Chen; D S Chen
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 6.  An update on the molecular genetics of hepatocellular carcinoma.

Authors:  Arief Suriawinata; Ruliang Xu
Journal:  Semin Liver Dis       Date:  2004-02       Impact factor: 6.115

7.  Prevalence of metastases in hepatocellular carcinoma: risk factors and impact on survival.

Authors:  Ming-Sing Si; Farin Amersi; S Raymond Golish; Jorge A Ortiz; Joseph Zaky; Debbie Finklestein; Ronald W Busuttil; David K Imagawa
Journal:  Am Surg       Date:  2003-10       Impact factor: 0.688

8.  Resection for extrahepatic recurrence of hepatocellular carcinoma.

Authors:  C M Lo; E C Lai; S T Fan; T K Choi; J Wong
Journal:  Br J Surg       Date:  1994-07       Impact factor: 6.939

9.  Hepatocellular carcinoma with metastasis to the kidney: report of a case.

Authors:  Y B Hsu; P H Lee; J C Sheu; D S Chen; H C Hsu
Journal:  J Formos Med Assoc       Date:  1994-01       Impact factor: 3.282

10.  Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection.

Authors:  Teresa Pollicino; Giovanni Squadrito; Giovanni Cerenzia; Irene Cacciola; Giuseppina Raffa; Antonio Craxi; Fabio Farinati; Gabriele Missale; Antonina Smedile; Claudio Tiribelli; Erica Villa; Giovanni Raimondo
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682

View more
  2 in total

Review 1.  A Systematic Review of Metastatic Hepatocellular Carcinoma to the Spine.

Authors:  C Rory Goodwin; Vijay Yanamadala; Alejandro Ruiz-Valls; Nancy Abu-Bonsrah; Ganesh Shankar; Eric W Sankey; Christine Boone; Michelle J Clarke; Mark Bilsky; Ilya Laufer; Charles Fisher; John H Shin; Daniel M Sciubba
Journal:  World Neurosurg       Date:  2016-05-13       Impact factor: 2.104

2.  Complete cure of a patient with HBV-associated hepatocellular carcinoma with lung metastasis using interferon and survival up to 108 months: A case report and literature review.

Authors:  Fang Wang; Hongmin Lv; Yan Li; Tao Han; Hui Liu; Kefeng Jia; Fang Liu; Yanying Gao; Fengmei Wang
Journal:  Oncol Lett       Date:  2018-06-28       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.